Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
$1.71B |
| 2 |
Eli Lilly
LLY
|
$1.55B |
| 3 |
Tesla
TSLA
|
$1.14B |
| 4 |
Boeing
BA
|
$935M |
| 5 |
TE Connectivity
TEL
|
$910M |
Top Sells
| 1 |
Apple
AAPL
|
$1.79B |
| 2 |
Visa
V
|
$1.57B |
| 3 |
General Dynamics
GD
|
$1.55B |
| 4 |
Morgan Stanley
MS
|
$1.29B |
| 5 |
Exelon
EXC
|
$1.15B |
Sector Composition
| 1 | Technology | 24.19% |
| 2 | Healthcare | 17.87% |
| 3 | Financials | 14.67% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
PTC Therapeutics
PTCT
$4.55B
| $216M | 0.04% |
4,787,123
-3,105,676
| -39% | -$140M |
|
352
BWX Technologies
BWXT
$15B
| $216M | 0.04% |
1,938,303
-1,031,699
| -35% | -$115M |
|
353
JB Hunt Transport Services
JBHT
$13.9B
| $216M | 0.04% |
1,263,391
+1,024,295
| +428% | +$175M |
|
354
Kymera Therapeutics
KYMR
$3.11B
| $214M | 0.04% |
5,307,326
+688,967
| +15% | +$27.7M |
|
355
LyondellBasell Industries
LYB
$17.7B
| $213M | 0.04% |
2,870,666
+757,612
| +36% | +$56.3M |
|
356
iShares Core MSCI EAFE ETF
IEFA
$150B
| $213M | 0.04% |
3,026,735
+778,779
| +35% | +$54.7M |
|
357
Ameris Bancorp
ABCB
$5.08B
| $212M | 0.04% |
3,393,197
-168,969
| -5% | -$10.6M |
|
358
Structure Therapeutics
GPCR
$1.27B
| $211M | 0.04% |
7,785,614
+15,843
| +0.2% | +$430K |
|
359
Kroger
KR
$44.8B
| $211M | 0.04% |
3,451,923
+722,135
| +26% | +$44.2M |
|
360
iShares Core S&P 500 ETF
IVV
$664B
| $210M | 0.04% |
356,329
-5,764
| -2% | -$3.39M |
|
361
Globus Medical
GMED
$8.18B
| $206M | 0.04% |
2,496,599
-81,891
| -3% | -$6.77M |
|
362
Akero Therapeutics
AKRO
$3.58B
| $205M | 0.04% |
7,376,961
-519,671
| -7% | -$14.5M |
|
363
Apogee Therapeutics
APGE
$2.26B
| $205M | 0.04% |
4,517,363
-297,037
| -6% | -$13.5M |
|
364
StepStone Group
STEP
$4.78B
| $202M | 0.04% |
3,485,680
-2,013,672
| -37% | -$117M |
|
365
Alkermes
ALKS
$4.94B
| $202M | 0.04% |
7,012,483
-5,645,762
| -45% | -$162M |
|
366
WESCO International
WCC
$10.7B
| $201M | 0.04% |
+1,111,989
| New | +$201M |
|
367
Denali Therapeutics
DNLI
$2.26B
| $201M | 0.04% |
9,847,951
-879,499
| -8% | -$17.9M |
|
368
Steven Madden
SHOO
$2.2B
| $201M | 0.04% |
4,718,033
-31,603
| -0.7% | -$1.34M |
|
369
Macerich
MAC
$4.74B
| $200M | 0.04% |
10,051,286
+8,988,665
| +846% | +$179M |
|
370
Belden
BDC
$5.14B
| $200M | 0.04% |
1,777,902
-354,984
| -17% | -$40M |
|
371
Neurocrine Biosciences
NBIX
$14.3B
| $199M | 0.04% |
1,457,425
+739,199
| +103% | +$101M |
|
372
Viavi Solutions
VIAV
$2.6B
| $198M | 0.04% |
19,614,684
+5,815,648
| +42% | +$58.7M |
|
373
SL Green Realty
SLG
$4.4B
| $197M | 0.04% |
2,893,454
-19,595
| -0.7% | -$1.33M |
|
374
Fortune Brands Innovations
FBIN
$7.3B
| $196M | 0.04% |
2,870,673
+1,110,021
| +63% | +$75.8M |
|
375
SPDR S&P 500 ETF Trust
SPY
$660B
| $196M | 0.04% |
334,686
-112,896
| -25% | -$66.2M |
|